ATRAのチャート
ATRAの企業情報
symbol | ATRA |
---|---|
会社名 | Atara Biotherapeutics Inc (アタラ・バイオセラピュ―ティクス) |
分野(sector) | Health Care ヘルスケア |
産業(industry) | Biotechnology: Biological Products (No Diagnostic Substances) |
業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連(Health Care) |
概要 | 事業概要 アタラ・バイオセラピューティックス(Atara Biotherapeutics Inc.)は臨床段階のバイオ医薬品会社である。同社は、重度の致命的な病気の患者の治療法の開発に注力している。同社は治療薬セグメントの開発および商業化事業を行っている。同社は同種異系または第三者由来の抗原特異的T細胞の開発に注力している。 T細胞は白血球の一種である。同社の製品候補であるATA129は、Epstein-Barrウイルス(EBV)の治療用のサードパティ派生Epstein-BarrウイルスCTLである。ATA188は、多発性硬化症の治療のために開発中である。サードパティ提供者のWT1-CTLであるATA520は、抗原Wilms Tumor 1(WT1)を発現する癌を標的とする。ATA520は第I相臨床試験中である。サードパティ由来のサイトメガロウイルスCTL(CMV-CTL)である同社のT細胞製品候補であるATA230は、難治性CMVの第II相臨床試験中である。 アタラ・バイオセラピュ―ティクスは米国のバイオ医薬品会社。筋消耗性疾患およびがんを対象に、未だ有効な治療方法がない医療ニ―ズに応える新薬の開発に注力する。新薬候補には末期の腎臓がん患者にみられる蛋白質・エネルギ―障害(PEW)治療用のPINTA 745、および卵巣がん治療用のSTM 434がある。 Atara Biotherapeutics, Inc.(@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. With its lead program in Phase 3 clinical development, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Its platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform to create a robust pipeline including: tab-cel® in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Improving patients' lives is its mission and it will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco and its leading-edge research, development and manufacturing facility is based in Thousand Oaks, California. |
本社所在地 | 611 Gateway Blvd. Suite 900 South San Francisco CA 94080 USA |
代表者氏名 | Isaac E. Ciechanover アイザック・E・チーチャナウバー |
代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO) |
電話番号 | +1 650-278-8930 |
設立年月日 | 41122 |
市場名 | NASDAQ National Market System |
ipoyear | 2014年 |
従業員数 | 185人 |
url | www.atarabio.com |
nasdaq_url | https://www.nasdaq.com/symbol/atra |
adr_tso | ― |
EBITDA | EBITDA(百万ドル) -160.94500 |
終値(lastsale) | 37.61 |
時価総額(marketcap) | 1705337179.33 |
時価総額 | 時価総額(百万ドル) 1674.051 |
売上高 | 売上高(百万ドル) 0.00000 |
企業価値(EV) | 企業価値(EV)(百万ドル) 1257.036 |
当期純利益 | 当期純利益(百万ドル) -158.73500 |
決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Atara Biotherapeutics Inc revenues was not reported. Net loss increased 74% to $92.3M. Higher net loss reflects Other Research and Development increase of 75% to $55.5M (expense) Other General and Administrative increase from $11.4M to $24.5M (expense) Stock-based Compensation in R&D increase of 53% to $6.3M (expense). |
ATRAのテクニカル分析
ATRAのニュース
Atara Biotherapeutics Stock: A Speculative Buy After A Difficult Year (NASDAQ:ATRA) 2023/02/09 17:01:51 Seeking Alpha
Atara has a cell therapy with a unique approach based on a novel allogeneic Epstein-Barr virus T-cell platform. Read what could be next for ATRA after a challenging year.
Atara Biotherapeutics Inc. (NASDAQ: ATRA) Stock Jumped 43.59% Over A Month – Is There Any Hope Of A Gain? 2023/02/09 14:30:00 Marketing Sentinel
During the last session, Atara Biotherapeutics Inc. (NASDAQ:ATRA)’s traded shares were 1.1 million, with the beta value of the company hitting 0.91. At the end of the trading day, the stock’s price was $5.04, reflecting an intraday loss of -7.69% or -$0.42. The 52-week high for the ATRA share is $16.07, that puts it down … Atara Biotherapeutics Inc. (NASDAQ: ATRA) Stock Jumped 43.59% Over A Month – Is There Any Hope Of A Gain? Read More »
Atara Biotherapeutics Inc earnings missed by $0.17, revenue fell short of estimates By Investing.com 2023/02/09 02:06:00 Investing.com
Atara Biotherapeutics Inc earnings missed by $0.17, revenue fell short of estimates
Atara Biotherapeutics: Q4 Earnings Snapshot 2023/02/08 21:21:30 WTOP
THOUSAND OAKS, Calif. (AP) — THOUSAND OAKS, Calif. (AP) — Atara Biotherapeutics Inc. (ATRA) on Wednesday reported a loss of…
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress | MarketScreener 2023/02/08 21:03:01 MarketScreener
Ebvallo™ EU Launch Activities Led by Pierre Fabre to Commence in Q1 2023 Discussions with FDA Progressing on Potential U.S. BLA for Tab-cel® ATA188 Phase 2 EMBOLD Study Primary Data… | February 8, 2023
Will Atara Biotherapeutics Inc. (NASDAQ: ATRA) Stock Boom Or Bust From Here? 2022/09/16 14:30:00 Marketing Sentinel
During the last session, Atara Biotherapeutics Inc. (NASDAQ:ATRA)’s traded shares were 1.99 million, with the beta value of the company hitting 0.97. At the end of the trading day, the stock’s price was $4.70. The 52-week high for the ATRA share is $20.04, that puts it down -326.38 from that peak though still a striking … Will Atara Biotherapeutics Inc. (NASDAQ: ATRA) Stock Boom Or Bust From Here? Read More »
Is Atara Biotherapeutics Inc. (NASDAQ: ATRA) A Stock A New Investor Should Consider Now? 2022/09/15 11:30:00 Stocks Register
Atara Biotherapeutics Inc. (NASDAQ:ATRA) shares, rose in value on Wednesday, September 14, with the stock price up by 2.84% to the previous day’s close as strong demand from buyers drove the stock to $4.70. Actively observing the price movement in the last trading, the stock closed the session at $4.57, falling within a range of … Is Atara Biotherapeutics Inc. (NASDAQ: ATRA) A Stock A New Investor Should Consider Now? Read More »
A stock that deserves closer examination: Atara Biotherapeutics Inc. (ATRA) 2022/09/12 12:16:00 US Post News
Atara Biotherapeutics Inc. (NASDAQ:ATRA) closed Friday at $4.82 per share, up from $4.75 a day earlier. While Atara Biotherapeutics Inc. has overperformed by 1.47%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ATRA fell by -68.02%, with highs and lows ranging from $20.04 to $2.83, whereas […]
Atara Biotherapeutics Inc. (NASDAQ: ATRA) Can Raise Stock -6.07% More 2022/08/23 14:30:00 Stocks Register
The trading price of Atara Biotherapeutics Inc. (NASDAQ:ATRA) closed lower on Monday, August 22, closing at $4.18, -6.07% lower than its previous close. Traders who pay close attention to intraday price movement should know that it fluctuated between $4.16 and $4.51. In examining the 52-week price action we see that the stock hit a 52-week … Atara Biotherapeutics Inc. (NASDAQ: ATRA) Can Raise Stock -6.07% More Read More »
NASDAQ:ATRA Shareholder Notice: Investigation over Possible Securities Laws Violations by Atara Biotherapeutics, Inc. 2022/08/18 16:30:00 SBWire
An investigation for investors in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) shares over potential securities laws violations by Atara Biotherapeutics, Inc. was announced. San Diego, CA -- ( SBWIRE ) -- 08/18/2022 -- Atara Biotherapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. Investors who purchased shares of Atara Biotherapeutics, Inc. (NASDAQ: ATRA), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Atara Biotherapeutics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made. San Francisco, CA based Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. On November 4, 2021, Atara Biotherapeutics, Inc issued a press release touting its T cell immunotherapy product candidate, ATA188.
Atara Biotherapeutics Inc. (NASDAQ:ATRA) Stock Plunged -44.42% So Far In 2022, What Analysts Expect Next? 2022/04/09 12:30:00 Marketing Sentinel
In last trading session, Atara Biotherapeutics Inc. (NASDAQ:ATRA) saw 0.55 million shares changing hands with its beta currently measuring 1.76. Company’s recent per share price level of $8.76 trading at -$0.31 or -3.42% at ring of the bell on the day assigns it a market valuation of $797.51M. That closing price of ATRA’s stock is … Atara Biotherapeutics Inc. (NASDAQ:ATRA) Stock Plunged -44.42% So Far In 2022, What Analysts Expect Next? Read More »
Atara Biotherapeutics names new technical chief (NASDAQ:ATRA) 2022/04/05 20:07:52 Seeking Alpha
Atara Biotherapeutics (ATRA) appoints biopharma executive Charlene Banard as its new chief technical officer. Banard comes to Atara from Novartis, where, as Global Head,…
Fujifilm Completes Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc. 2022/04/04 20:02:00 GlobeNewswire
Facility acquisition includes 134 employees in manufacturing and quality positions Facility acquisition includes 134 employees in manufacturing and quality positions
Is Atara Biotherapeutics Inc. (NASDAQ: ATRA) A Good Pick For New Investors Now? 2022/03/12 17:00:00 Stocks Register
Atara Biotherapeutics Inc. (NASDAQ:ATRA) shares, rose in value on Friday, 03/11/22, with the stock price down by -2.59% to the previous day’s close as strong demand from buyers drove the stock to $9.02. Actively observing the price movement in the last trading, the stock closed the session at $9.26, falling within a range of $9.00 … Is Atara Biotherapeutics Inc. (NASDAQ: ATRA) A Good Pick For New Investors Now? Read More »